Test Price
2,800 AED✅ Home Collection Available
FHL1 Gene Emery-Dreifuss Muscular Dystrophy Type 6 Genetic Test in UAE | 2800 AED | DHA Licensed
Executive Summary & Core Metrics
- ✓ Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO 9001:2015 accredited processing.
- ✓ Premium Logistics: Pain-free hospital-grade home collection via ISO-certified cold-chain and VIP mobile phlebotomy.
- ✓ Clinical Guidance: Telephonic post-test clinical guidance in result interpretation by a specialist physician.
- ✓ Insurance: Direct billing verification via WhatsApp +971 54 548 8731.
This advanced genetic test provides complete sequencing of the FHL1 gene using next-generation sequencing (NGS) with 99.9% diagnostic accuracy under ISO 9001:2015. It includes safe home collection via cold-chain mobile phlebotomy, post-result specialist consultation, and full compliance with UAE Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
Test Overview & Methodology
The FHL1 gene NGS test detects pathogenic variants responsible for Emery-Dreifuss Muscular Dystrophy Type 6 (EDMD6), a rare X-linked neuromuscular disorder marked by early joint contractures, slowly progressive muscle weakness, and life-threatening cardiac conduction defects. This high-coverage next-generation sequencing provides a definitive molecular diagnosis, enabling tailored cardiac surveillance, orthopedic management, and accurate family risk assessment.
| Feature | Our Test (NGS) | Closest Alternative (Sanger / Small Panel) |
|---|---|---|
| Precision & Coverage | Full-gene analysis of FHL1 with 100% coverage of all exons, intron-exon boundaries, and deep intronic regions | Targeted sequencing limited to known hotspots; may miss novel or large deletions/duplications |
| Methodology | NGS on Illumina NovaSeq™ platform with clinically validated bioinformatics pipeline | Sanger sequencing or small capture panel; lower sensitivity for mosaicism |
| Turnaround Time | 3–4 Weeks | 4–8 Weeks (fragmented workflow) |
Physician Insight & Safety Protocols
“As a consultant medical geneticist, I recognise the profound anxiety that a genetic test for muscular dystrophy brings. This FHL1 analysis provides a clear molecular answer, but it must always be correlated with your clinical history, cardiac assessments, and family pedigree. Together, we will translate this information into a compassionate, personalised management plan that safeguards your heart and mobility.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Safety Advisory
⚠ Medication Warning
Do not discontinue prescribed medication without consulting your doctor. Always inform your physician about any ongoing therapies before the blood draw.
Exclusion Criteria & Emergency Red Flags
- If you experience sudden chest pain, palpitations, fainting, or severe shortness of breath, seek emergency cardiac care immediately – these may signal dangerous arrhythmias or cardiomyopathy associated with EDMD.
- Blood draw is contraindicated in patients with severe uncontrolled coagulopathy or ongoing high-dose anticoagulant therapy without physician clearance.
- This test should be ordered only after a formal genetic counselling session and pedigree chart documentation, as required by UAE clinical governance standards for minors and vulnerable groups.
Patient FAQ & Clinical Guidance
1. What is the FHL1 gene test and why is it performed?
The FHL1 gene NGS test identifies mutations causing Emery-Dreifuss muscular dystrophy type 6, enabling accurate diagnosis, family screening, and tailored management. This test analyzes the entire FHL1 gene for sequence variants and copy-number changes using high-throughput sequencing, offering a definitive explanation for muscle weakness, joint stiffness, and cardiac issues. Results guide neurologists, cardiologists, and genetic counselors in prognosis and preventive interventions.
2. How accurate is this NGS test, and can it detect all mutations?
Our NGS achieves 99.9% diagnostic sensitivity for FHL1 coding regions, detecting point mutations, indels, and copy number variants. The analytical pipeline is validated against international standards and includes orthogonal confirmation of pathogenic findings. Rare deep intronic or epigenetic modifications may require additional targeted study, but comprehensive clinical correlation minimizes diagnostic gaps.
3. What is the sample collection process, and is home service available?
A trained phlebotomist performs a pain-free blood draw at your home, or you can provide DNA on an FTA card, ensuring convenience and sample stability. The sample is transported in an ISO-certified cold chain from 8 AM to 11 PM daily. Minimal preparation is required: hydration and a brief genetic counselling session beforehand can be arranged at the same visit.
UAE Regulatory & Data Privacy Adherence
Data Protection & Health Information Security: This test and its associated data processing fully comply with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic information is handled with strict confidentiality, stored in encrypted systems, and shared only with your explicit consent as required by law.
Medical Liability: Clinical safety and patient consent requirements are governed by Federal Decree-Law No. 4 of 2016 on Medical Liability. Our laboratory maintains ISO 9001:2015 accreditation (Cert: INT/EGQ/2509DA/3139) to ensure world-class quality standards in every step of the testing process.
Clinical & Logistical Metadata
| Test Name | FHL1 Gene Sequencing (Emery-Dreifuss Muscular Dystrophy Type 6) – Next-Generation Sequencing |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood (3-5 mL in EDTA tube) or FTA Card (Dried Blood Spot) |
| Methodology Used | Next-Generation Sequencing (Illumina NovaSeq™) with custom bioinformatics pipeline |
| ICD-10-CM Code | G71.09 (Other specified muscular dystrophies) |
| LOINC Code | 51969-4 (FHL1 gene [Presence] in Blood or Tissue by Molecular genetics method) |
| DHA Facility License & Laboratory Address | License No. 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians